Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
|Articles|May 1, 2010

Applied Clinical Trials

  • Applied Clinical Trials-05-01-2010
  • Volume 0
  • Issue 0

Refutable Rates

Author(s)TTC

Perhaps few issues elicit more interest in clinical trial agreements (clinical grants) than the overhead portion of the contract. Clinical trial agreements typically have three parts: procedures, nonprocedures, and overhead.

Perhaps few issues elicit more interest in clinical trial agreements (clinical grants) than the overhead portion of the contract. Clinical trial agreements typically have three parts: procedures, nonprocedures, and overhead.

Procedures are those medical activities directly related to the protocol that may range from a blood draw to something far more complex. Nonprocedures include an equally broad range of activities, such as study coordinator time, facility charges, patient reimbursement, and meals.

Overheads are indirect institutional costs allocated to individual departments and their programs. These indirect costs can include such illustrative items as costs of the institution's general management, building maintenance, general administration, and in some cases, general marketing efforts.

Here we report U.S. overhead rates. Few pharmaceutical companies are willing to pay overhead costs to office-based investigators. However, most clinical trial agreements with institutions include an overhead figure.

Clinical grant data in GrantPlan from companies conducting 76% of all clinical studies demonstrate that, in general, overheads at academic medical centers are slightly higher than at other institutions.

Instiutions vs Actual Agreements in U.S.-Based Overhead Figures

Particularly noteworthy though is the significant difference between the overhead rate reported by the institution, frequently used as the starting point in negotiations, and the actual amount accepted in the contract by the institution.—TTC (For more information, please contact help@ttc-llc.com.)

Articles in this issue

over 16 years ago

Research Integrity Gets Boost

over 16 years ago

EDC & EHR Integration

over 16 years ago

Me-Too's Struggle

over 16 years ago

Clinical Trials for Kids

over 16 years ago

act supplement cover

over 16 years ago

A Patient Universe

over 16 years ago

Conversations With Study Volunteers

Related to this article

What Needs to Happen Beyond the Clinical Trial Modernization Act
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.